Trial reportProceedings of the National Academy of Sciences of the United States of America2005
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 218 citations in OpenAlex.
- Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.JCI insight · 2021Trial
- Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.The Journal of clinical investigation · 2015Trial
- Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.The lancet. Diabetes & endocrinology · 2013Trial
- IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.The Journal of allergy and clinical immunology · 2012Trial
- Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.PloS one · 2012Trial
- Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.PloS one · 2012Trial
- Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques.The Journal of investigative dermatology · 2010Trial
- Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.BMC dermatology · 2010Trial
- Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.Journal of translational medicine · 2007Trial
- Design of aptamer peptides for immunomodulation.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Dual targeting of CD244 and CD2 by a viral-immunoevasin-guided engineered CD48-Fc mutant for T- and NK-cell modulation.Frontiers in immunology · 2026Article
- Current Landscape of Chronic Inflammatory Dermatoses: Where We Are and Where We Are Heading.Current issues in molecular biology · 2024Article
- Psoriasis and Psoriatic Arthritis-Associated Genes, Cytokines, and Human Leukocyte Antigens.Medicina (Kaunas, Lithuania) · 2024Review
- Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα.Dermatology and therapy · 2024Article
- Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes.JCI insight · 2023Article
- Interleukins 20 and 8 - less widely known cytokines in psoriasis.Postepy dermatologii i alergologii · 2023Review
- Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles.International journal of molecular sciences · 2023Article
- Building an infrastructure to support the development, conduct, and reporting of informative clinical studies: The Rockefeller University experience.Journal of clinical and translational science · 2023Article
- Targeting protein-protein interaction for immunomodulation: A sunflower trypsin inhibitor analog peptidomimetic suppresses RA progression in CIA model.Journal of pharmacological sciences · 2022Article
- The biological basis of disease recurrence in psoriasis: a historical perspective and current models.The British journal of dermatology · 2022Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Psoriasis vulgaris, a skin disease that is considered to be the result of a type 1 autoimmune response, provides an opportunity for studying the changes that occur in a target-diseased tissue during innovative immunotherapies. To gain a more comprehensive picture of the response to an approved biological therapy, we studied alfacept, which is a CD2 binding fusion protein. We examined T cells, dendritic cells (DCs), and expression of a number of inflammatory genes. In 22 patients, 55% demonstrated a clear histological remission of the disease, with a 73% reduction in lesional lymphocytes and a 79% decrease in infiltrating CD8+ cells. Only histological responders showed marked reductions in the tissue expression of inflammatory genes IFN-gamma, signal transducer and activator of transcription 1, monokine induced by IFN-gamma, inducible NO synthase, IL-8, and IL-23 subunits. Parallel decreases in CD83+ and CD11c+ DCs also were measured by immunohistochemistry. Because we observed that alefacept binds primarily to T cells and not DCs, we suggest that T cells are the primary target for therapy, but that DCs and a spectrum of type 1 inflammatory genes are coordinately suppressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.